These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38665034)

  • 21. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
    Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
    Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hepatocellular carcinoma after hepatitis C virus cure.
    Luna-Cuadros MA; Chen HW; Hanif H; Ali MJ; Khan MM; Lau DT
    World J Gastroenterol; 2022 Jan; 28(1):96-107. PubMed ID: 35125821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
    PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
    Roche B; Coilly A; Duclos-Vallee JC; Samuel D
    Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis.
    Galati G; Muley M; Viganò M; Iavarone M; Vitale A; Dell'Unto C; Lai Q; Cabibbo G; Sacco R; Villa E; Trevisani F
    Expert Opin Drug Saf; 2019 Jul; 18(7):603-610. PubMed ID: 31067134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
    Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
    PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.
    Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
    Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.
    Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN
    Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.
    Shiha G; Waked I; Soliman R; Elbasiony M; Gomaa A; Mikhail NNH; Eslam M
    Liver Int; 2020 Nov; 40(11):2828-2833. PubMed ID: 32946647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.
    Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R
    Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis.
    Lv GJ; Ji D; Yu L; Chen HY; Chen J; He M; Wang WC; Wang HB; Tsang C; Wang J; Yu ML; Lau G;
    Hepatol Int; 2024 Oct; 18(5):1459-1471. PubMed ID: 38965190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C.
    Na SK; Song BC
    Clin Mol Hepatol; 2019 Sep; 25(3):234-244. PubMed ID: 30661334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
    Tholey DM; Ahn J
    Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals.
    Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
    Gut Liver; 2024 Jan; 18(1):147-155. PubMed ID: 37076993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.